Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
ID: 338828Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/338828

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-127.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting the development of innovative technologies in biomedical research. This initiative seeks applications that focus on creating and validating prototypes of new technological tools, methods, and techniques, emphasizing projects that present significant technical challenges and represent novel advancements over existing technologies. Eligible applicants include a wide range of organizations, such as higher education institutions, non-profits, and tribal colleges, while applications must avoid addressing specific biological questions and instead concentrate on technology development. Interested parties should note that the application deadline is May 7, 2025, and can find more information at the provided link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-127.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Funding Opportunity Announcement (FOA) for the development of innovative technologies in biomedical research that do not involve clinical trials. The Focused Technology Research and Development (R01) program invites applications aimed at creating and validating prototypes of new technological tools, methods, and techniques essential for advancing biomedical research. The program emphasizes projects with substantial technical challenges, urging applicants to represent novel advancements over existing technologies. The FOA specifies that applications must avoid addressing specific biological questions and should instead concentrate on technology development, which includes algorithms, laboratory instruments, and biological reagents. Eligible organizations range from higher education institutions to non-profits, while submission processes require registrations with Grants.gov and eRA Commons. Key dates include application due dates, with a maximum project funding period of up to five years. The review process evaluates scientific merit, impact on the field, investigator qualifications, and innovation potential, ensuring that selected projects significantly contribute to the biomedical research landscape. The initiative not only fosters technological innovation but also aims to broaden the range of investigative questions within the biomedical domain.
    Similar Opportunities
    Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting innovative technology projects that advance biomedical research. Eligible applicants include a diverse range of institutions, such as Historically Black Colleges and Universities, Tribal Colleges, and various community-based organizations, with a focus on projects that demonstrate proof-of-concept and the development of working prototypes without integrating clinical trials. This initiative is crucial for fostering technological advancements that enhance understanding of biological processes, with no budget cap and a maximum project duration of five years. Interested applicants can find more information and application guidelines at NIH Grants, with proposals due by January 7, 2028.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory research grants (R21) aimed at developing innovative technologies in biomedical research. This initiative seeks applications that propose high-risk, high-reward projects focused on technology development without existing proof of concept, specifically excluding clinical trials. The funding amount is capped at $275,000 in direct costs over two years, with a maximum of $200,000 available in any single year. Interested applicants, including higher education institutions and nonprofit organizations, must adhere to submission guidelines and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The application deadline is January 7, 2028.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled “Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed),” aimed at supporting exploratory research for innovative biomedical technologies. This initiative focuses on high-risk projects that have not yet established feasibility, specifically targeting the development of tools such as laboratory instruments, algorithms, and chemical reagents, while excluding applications that address specific biological questions or present existing proof of concept data. Eligible applicants can request funding of up to $275,000 over two years, with a maximum of $200,000 in any single year, and applications are due by May 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-126.html.
    Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional)" aimed at developing medical technologies that address health disparities among underserved populations in the U.S. This initiative encourages grant applications focused on creating effective, affordable, culturally acceptable, and accessible medical solutions, including devices, imaging systems, and telehealth innovations, while emphasizing the importance of formal collaborations with healthcare organizations serving these populations. The NIH plans to allocate approximately $2.4 million for this initiative, with an award ceiling of $500,000 per project, and expects to fund 3-4 awards over a project duration of up to four years. Interested applicants must submit their proposals by May 2, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment" funding opportunity (FOA PAR-21-166). This initiative aims to foster collaborations between academic institutions and industry to translate scientific discoveries into practical diagnostic and therapeutic solutions, specifically targeting the development of methods or tools for disease prevention, diagnosis, and treatment. The program is particularly significant as it seeks to bridge gaps in healthcare technology and enhance the effectiveness of disease management across various settings, while explicitly excluding clinical trials. Eligible applicants can receive funding up to $499,000 per year for a maximum of five years, with applications due by January 8, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the funding announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-21-166.html.
    NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) to support discrete scientific projects aligned with the interests of various NIH Institutes and Centers. This grant is specifically designed for projects that do not involve clinical trials, focusing instead on advancing health-related research and development. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and tribal governments, with no fixed budget limits, although applicants must justify their requested funding. Interested parties should note that the application deadline is January 7, 2025, and can find more information by contacting the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visiting the official announcement at http://grants.nih.gov/grants/guide/pa-files/PA-20-185.html.
    Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the opportunity titled "Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding initiative aims to support exploratory research projects focused on the early-stage development of innovative technologies that enhance the quality, handling, and preservation of cancer-related biospecimens, addressing issues such as pre-analytical degradation. The initiative is part of the broader Innovative Molecular Analysis Technologies (IMAT) Program and seeks to advance cancer research, early detection, and treatment while addressing health disparities. Eligible applicants include a diverse range of institutions and organizations, with a maximum funding amount of $150,000 per year for up to three years. The application deadline is October 3, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)" aimed at supporting discrete research projects across various scientific fields, excluding clinical trials. This grant encourages applications from a diverse range of eligible entities, including higher education institutions, nonprofits, and organizations serving underrepresented communities, with the goal of fostering innovative research that enhances public health and scientific knowledge. The funding does not impose limits on application budgets, provided they reflect actual project needs, and allows for a maximum project duration of five years. Interested applicants can find more information and guidelines at the NIH grants website and should direct inquiries to grantsinfo@nih.gov, with the application deadline set for January 7, 2028.
    NIH Research Project Grant (Parent R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIH Research Project Grant, designated as the Parent R01 Clinical Trial Required (Funding Opportunity Number PA-25-305). This grant supports discrete research projects that include at least one clinical trial and align with the scientific missions of participating NIH Institutes and Centers. The initiative aims to foster innovative health-related research and enhance scientific resources, with applications accepted from a diverse range of organizations, including higher education institutions and community-based organizations. Applications will open on January 5, 2025, with subsequent submission deadlines throughout 2025 and 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This grant aims to support exploratory research projects that focus on the development and validation of innovative technologies to enhance the quality and handling of cancer-relevant biospecimens, addressing significant gaps in cancer research methodologies. The initiative is part of the National Cancer Institute's (NCI) broader Innovative Molecular Analysis Technologies (IMAT) Program, which seeks to improve cancer biology research, early detection, clinical diagnosis, and treatment, while also tackling health disparities. Eligible applicants can receive up to $300,000 per year for a maximum of three years, with a submission deadline of October 3, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-004.html.